Skip to main content
SpringerLink
Log in

Evidence-Based Guidelines for Treatment of Hepatocellular Carcinoma in Japan

  • Chapter
  • First Online:
Hepatocellular Carcinoma:

  • 1224 Accesses

Abstract

Hepatocellular carcinoma (HCC) has five characteristics that are strikingly different from those of other malignant tumors of the digestive system: (1) a strong causal relationship with hepatitis viruses (especially type B and type C), (2) a major impact of the status of hepatic functional reserve and liver damage on the choice of treatment and the prognosis, (3) a high recurrence rate, with many of the recurrences developing within the liver, and the existence of two major routes of recurrence, i.e., multicentric carcinogenesis and intrahepatic metastasis, (4) the possibility of performing effective treatment, if confined to the liver and liver functional reserve permits, and (5) the existence of a clear outcome determinant as vascular invasion. Because of these characteristics, choosing the method of treatment for HCC is not easy, although several useful methods are available to treat HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Makuuchi M, Kokudo N (2006) Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 12:828–829

    PubMed  Google Scholar 

  2. Makuuchi M, Kokudo N, Arii S et al (2008) Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38:37–51

    Article  PubMed  Google Scholar 

  3. Liver Cancer Study Group of Japan (1997) Classification of primary liver cancer. Kanehara & Co., Ltd., Tokyo p. 21

    Google Scholar 

  4. Makuuchi M, Kosuge T, Takayama T et al (1993) Surgery for small liver cancers. Semin Surg Oncol 9:298–304

    Article  CAS  PubMed  Google Scholar 

  5. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  CAS  PubMed  Google Scholar 

  6. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236

    Article  PubMed  Google Scholar 

  7. Ishizawa T, Hasegawa K, Aoki T et al (2008) Multiple tumors and concomitant portal hypertension are not operative contraindications for hepatocellular carcinoma. Gastroenterology 134:1908–1916

    Article  PubMed  Google Scholar 

  8. Vauthey JN, Lauwers GY, Esnaola NF et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536

    Article  PubMed  Google Scholar 

  9. Arii S, Yamaoka Y, Futagawa S et al (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 32:1224–1229

    Article  CAS  PubMed  Google Scholar 

  10. Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739

    Article  PubMed  Google Scholar 

  11. Minagawa M, Makuuchi M, Takayama T et al (2001) Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 233:379–384

    Article  CAS  PubMed  Google Scholar 

  12. Eddy DM (1990) Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 263:3077, 3081, 3084

    Google Scholar 

  13. Kokudo N, Sasaki Y, Nakayama T et al (2007) Dissemination of evidence-based clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons, and primary care physicians. Gut 56:1020–1021

    Article  PubMed  Google Scholar 

  14. Lencioni RA, Allgaier HP, Cioni D et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–240

    Article  PubMed  Google Scholar 

  15. Shiina S, Teratani T, Obi S et al (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129:122–130

    Article  PubMed  Google Scholar 

  16. Huang GT, Lee PH, Tsang YM et al (2005) Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 242:36–42

    Article  PubMed  Google Scholar 

  17. Chen MS, Li JQ, Zheng Y et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for hepatocellular carcinoma. Ann Surg 243:321–328

    Article  PubMed  Google Scholar 

  18. Hasegawa K, Kokudo N, Makuuchi M (2008) Surgery or ablation for hepatocellular carcinoma? Ann Surg 247:557–558

    Article  PubMed  Google Scholar 

  19. Hasegawa K, Makuuchi M, Takayama T, et al. for the Liver Cancer Study Group of Japan (2008) Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 49:589–594

    Article  PubMed  Google Scholar 

  20. Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group (2007) Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 13(11 Suppl 2): S48–S54

    Google Scholar 

  21. Llovet JM, Ricci S, Mazzaferro V, et al. for SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, University of Tokyo, Tokyo, Japan

    Kiyoshi Hasegawa MD, PhD

  2. Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan

    Norihiro Kokudo

Authors
  1. Kiyoshi Hasegawa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norihiro Kokudo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ambulatory Care Building, 2nd Floor, Department of Surgery, University of Louisville, S. Jackson Street 550, Louisville, 40202, Kentucky, USA

    Kelly M. McMasters

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hasegawa, K., Kokudo, N. (2011). Evidence-Based Guidelines for Treatment of Hepatocellular Carcinoma in Japan. In: McMasters, K. (eds) Hepatocellular Carcinoma:. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-522-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-522-4_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60327-521-7

  • Online ISBN: 978-1-60327-522-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation